Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mizuho Financial Group Inc. Sponosred ADR (Japan) (MFG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Mizuho Financial Group Inc. Sponosred ADR (Japan)Trade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Mizuho Financial Group Inc. Sponosred ADR (Japan) vs Recursion Pharmaceuticals Inc — how do they compare? Mizuho Financial Group Inc. Sponosred ADR (Japan) trades at $10.41 (market cap $132.18B), while Recursion Pharmaceuticals Inc trades at $4.02 (market cap $2.31B). The key difference: Mizuho Financial Group Inc. Sponosred ADR (Japan) is far larger — about 57.2× Recursion Pharmaceuticals Inc's market cap, and Mizuho Financial Group Inc. Sponosred ADR (Japan) pays a 1.7% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mizuho Financial Group Inc. Sponosred ADR (Japan) for 0 Days and Recursion Pharmaceuticals Inc for 22 Days on average.

MFGRXRX
Market Cap
$132.18B$2.31B
Volume
3,264,66240,478,768
Sector
FinancialsHealth
52-Week High
$11.45$6.79
52-Week Low
$6.09$2.84
Typical Hold Time
0 Days22 Days
Enterprise Value
$35.48T$1.83B
Dividend Yield
1.7%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mizuho Financial Group Inc. Sponosred ADR (Japan)

No Aura AI signal available yet.

Recursion Pharmaceuticals Inc

RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.

The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MFG
100% Buy0% Sell
Avg holding period · 0 Days
RXRX
8% Buy92% Sell
Avg holding period · 22 Days

About Mizuho Financial Group Inc. Sponosred ADR (Japan)

Mizuho Financial Group is a Japanese financial services company offering banking, trust, securities, and asset management services. It serves retail, corporate, and institutional clients globally.

Read more on MFG →

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX →